Cumbre Pharmaceuticals is considering partnering proposals for its clinical candidate CBR-2092, Research Programs and Discovery Assets (inc. bacterial pathogen and small molecule libraries).   Interested parties should contact Michael Bakes.  A confidential information package is available by entering into a standard form confidentiality agreement.